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A B S T R A C T
Although a lot of information can be found on the specific dual role of the endocannabinoid system in the
emotional-related responses, little is known whether stimulation or inhibition of the cannabinoid (CB) receptors
may affect the activity of the frequently prescribed antidepressant drugs. Our interests have been particularly
focused on the potential influence of the CB2 receptors, as the ones whose central effects are relatively poorly
documented when compared to the central effects of the CB1 receptors. Therefore, we evaluated the potential
interaction between the CB2 receptor ligands (i.e., JWH133 – CB2 receptor agonist and AM630 – CB2 receptor
inverse agonist) and several common antidepressant drugs that influence the monoaminergic system (i.e.,
imipramine, escitalopram, reboxetine). In order to assess the antidepressant-like effects we used two widely
recognized behavioural tests, the mouse forced swim test (FST) and the tail suspension test (TST). Brain con-
centrations of the tested antidepressants were evaluated by the HPLC method. Intraperitoneal co-administration
of per se ineffective doses of JWH133 (0.25mg/kg) or AM630 (0.25mg/kg) with imipramine (15mg/kg), es-
citalopram (2mg/kg), and reboxetine (2.5mg/kg) significantly shortened the immobility time of mice in the FST
and the TST, whereas it did not disturb their spontaneous locomotor activity. Furthermore, the brain levels of
antidepressants were not changed. Summarizing, the results of the present study revealed that both activation
and inhibition of the CB2 receptor function have a potential to strengthen the antidepressant activity of drugs
targeting the monoaminergic system. Most probably, the described interaction has a pharmacodynamic back-
ground.
1. Introduction
The endocannabinoid system has attracted clinicians attention for
decades as an endogenous homeostatic system associated with a large
number of neurotransmitters and their pathways, and implicated in
numerous physiological functions, including an inflammatory process,
pain, or emotions. The endocannabinoid system consists of the en-
dogenous arachidonate-based lipids referred to as “endocannabinoids”
(such as anandamide and 2-arachidonoylglycerol), enzymes responsible
for their synthesis (N-acylphosphatidylethanolamine-phospholipase D
and diacylglycerol lipase) and degradation (fatty acid amide hydrolase
and monoacylglycerol lipase), and the cannabinoid CB receptors (for
review see Refs. [1,2]). Thus far, two types of typical CB receptors,
encoded by CNR1 and CNR2 genes, have been described. Both CB1 and
CB2 receptors bind endogenous and exogenous cannabinoids with high
affinity. Due to specific mechanism of action of CB receptors, on the one
hand the endocannabinoid system can help to restore the brain balance
after exposure to different stressors, but on the other hand, it is involved
in the pathogenesis of certain mental disturbances, like anxiety, stress,
aggressive behavior, or depression. Until recently, only CB1 receptors
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were thought to be implicated in the development of mental diseases as
the ones that are expressed both in the periphery and the brain. CB2
receptors were mainly considered as the peripheral receptors. It was
believed that they were distributed almost exclusively within the im-
mune cells and thus, that they have only the immunomodulatory role
(i.e., regulation of cytokines or migration of immune cells) (for review
see Refs. [1–3]). However, several research team have found out that
CB2 receptors are also localized in the rodent [4] and human central
nervous system [5–7]. At first, their presence in the brain was linked to
existence of pathological conditions, like Alzheimer’s disease [8],
multiple sclerosis, amyotrophic lateral sclerosis [9], or tumours [10],
but then, they were also identified under physiological conditions [5].
CB2 receptors are localized in the spinal nucleus, olfactory nucleus,
thalamus, hippocampus, amygdala, cerebral cortex, and cerebellum
[11,12]. They are mainly distributed post-synaptically, but they can
also be found in the presynaptic areas. Functional effects of CB2 re-
ceptors that prove their presence in the brain have also been described
in literature. It has been revealed that CB2 receptors are involved in the
inflammatory responses that accompany the neurodegenerative pro-
cesses [8], in stress-induced neuroinflammation [13], schizophrenia,
alcohol preference in mice, alcoholism in humans [14], drug abuse,
motor function, and emotionality [4]. Onaivi et al. [4] reported a re-
duced expression of CB2 receptors in the striatum and midbrain of mice
that developed alcohol preference.
Involvement of CB2 receptors in the development of depression has
also been suggested. Deletion of CB2 receptors in mice with C57BL/6 J
congenic background induced depression-like behavior in the TST [15],
whereas genetically-induced lowered CB2 receptor function (in the Cnr2
heterozygote knock-out mice) was associated with an increased sus-
ceptibility to depression when exposed to immune or emotional stres-
sors (i.e., poly I:C or chronic mild stress, respectively) [16]. Reduction
of CB2 receptors in the hippocampus was observed in mice that had
been subjected to the chronic unpredictable mild stress [17]. In turn,
García-Gutiérrez et al. [17] found out that the genetically-induced
overexpression of CB2 receptors exerted an antidepressant-like effects in
the TST and the novelty-suppressed feeding test in mice with swiss ICR
congenic background. Moreover, these animals presented a higher level
of the brain-derived neurotrophic factor (BDNF) in the hippocampus
and they were resistant to stressful depressogenic-like situations in the
chronic unpredictable mild stress model. Both stimulation of CB2 re-
ceptors by their selective agonists (GW405833, JWH133, or β-car-
yophyllene) [18–20] as well as inhibition by their selective inverse
agonist (AM630) [17,20] produced an antidepressant-like activity in
the FST and/or the TST in naïve albino Swiss [20], C57BL/6 [19], ICR
Swiss [17] mice, or in rats that underwent chronic constriction injury
[18]. Additionally, treatment with CB2 receptor ligands inhibited the
development of the depressive-like behaviour in mice [17] and rats
[21] subjected to the chronic unpredictable stress. Ishiguro et al. [14]
suspected association between genetic variants of the CB2 gene and
depression in Japanese people.
Although a lot of information can be found on the specific dual role
of the endocannabinoid system in the emotional-related responses, little
is known whether stimulation or inhibition of CB receptors may affect
the activity of the frequently prescribed antidepressant drugs. This
subject seems to be quite important, in the view of the fact that more
than 322 million people suffer from depression and that the efficacy of
available drugs is not satisfactory. Hence, new (even controversial)
treatment options are necessary. Our interests have been particularly
focused on the potential influence of the CB2 receptors, as the ones
whose central effects are relatively poorly documented when compared
to the central effects of the CB1 receptors. For this purpose, we eval-
uated the potential interaction between CB2 receptor ligands (i.e.,
JWH133 – CB2 receptor agonist and AM630 – CB2 receptor inverse
agonist) and three common antidepressant drugs that influence the
monoaminergic system (i.e., imipramine – a tricyclic antidepressant,
escitalopram – a selective serotonin reuptake inhibitor, and reboxetine
– a selective noradrenaline reuptake inhibitor). According to the lit-
erature data [22], JWH133 has a very high affinity towards CB2 re-
ceptors (i.e., Ki= 3.4 ± 1 nM) and exhibits 200-fold selectivity for
them over CB1 receptors. AM630 also binds selectively to CB2 receptors,
with a CB2/CB1 affinity ratio of 165 and Ki= 31.2 nM at the CB2 re-
ceptor [23]. Being an inverse agonist of CB2 receptors, AM630 has both
affinity towards CB2 receptors and negative intrinsic activity. It binds to
the constitutively activated receptors and decreases their activity below
the basal level [24]. Thus, AM630 acts oppositely to JWH133. In order
to assess the antidepressant-like effects we used two widely recognized
behavioural tests, the mouse FST and the TST.
2. Materials and methods
2.1. Animals
The experiments were carried out on male Albino Swiss mice
(25–30 g). Animals were maintained in standard cages (8 mice/cage)
placed in environmentally controlled rooms (humidity ca. 45–55%,
temperature of 22–23 °C, 12 h light/dark cycle). They were given water
and food ad libitum. All performed procedures were planned in ac-
cordance with binding law related to the experimental studies on an-
imal models, and they were approved by the Local Ethics Committee.
2.2. Drug administration
JWH133 ((6aR,10aR)-3-(1,1-Dimethylbutyl)-6a,7,10,10a-tetra-
hydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran, 0.25mg/kg, Tocris) and
AM630 (6-Iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-
methoxyphenyl)methanone, 0.25mg/kg, Tocris) were suspended in
Tween 80 solution (1%). Imipramine hydrochloride (15mg/kg, Sigma-
Aldrich), escitalopram oxalate (2 mg/kg, Sigma-Aldrich), and rebox-
etine mesylate (2.5 mg/kg, Abcam Biochemicals) were dissolved in
physiological saline. The tested suspensions/solutions were adminis-
tered intraperitoneally (ip): imipramine, escitalopram, and reboxetine
were given 60min before behavioural tests, whereas JWH133 and
AM630 were given 30min before behavioural tests. The pretreatment
schedules and doses were selected on the basis of the literature data
[25] and were confirmed in the preliminary tests carried out in our lab.
The control mice received ip injections of vehicles.
2.3. Forced swim test (FST)
The FST was performed according to method that we used before
[26]. Each mouse was placed individually into glass cylinders (height
25 cm, diameter 10 cm) containing 10 cm of water at 23–25 °C and it
was left there for 6min. The immobility time of animals was recorded
between the 2nd and the 6th min of the test. A given mouse was judged
immobile when it stopped struggling and remained floating motionless
in the water. Movements necessary to keep animal’s head above the
water level were acceptable.
2.4. Tail suspension test (TST)
The TST was performed according to the method that we used be-
fore [27]. Each mouse was suspended by the tail (2 cm from the end of
the tail) using adhesive tape and it was left hanging for 6min. Though
the immobility time in the TST can be measured for the whole duration
of the test, we recorded the activity of animals for the last 4 min. Si-
milarly to the situation observed in the FST, animals at the beginning of
the TST usually show an increased escape-oriented struggling, which
lasts ca. 1–2min [28]. In order to avoid potential confounding of the
results, the first 2 min of the test was treated as a habituation period. A
given mouse was judged immobile when it stopped moving its body and
limbs. Only movements necessary to breathe were acceptable.
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2.5. Spontaneous locomotor activity
Spontaneous locomotor activity was measured automatically, as
was described before [26]. We used an activity meter Opto-Varimex-4
Auto-Track (Columbus Instruments, USA) that contains plexiglas cages
with lids (43× 43×32 cm) equipped with a set of four infrared
emitters and four detectors monitoring mice movements. Each animal
was placed individually in the cage. A distance travelled by a given
animal was recorded between the 2nd and the 6th min of the test. This
time interval corresponded with the one analyzed in the TST and the
FST.
2.6. Determination of the antidepressant levels in brain homogenates
New cohorts of animals were used for the biochemical studies. The
tested mice were decapitated 60min after injection of the anti-
depressant drug (with or without JWH133 or AM630). Their brains
were dissected and frozen. Imipramine, desipramine (i.e., an active
metabolite of imipramine), escitalopram, and reboxetine brain levels
were determined with use of the high-performance liquid chromato-
graphy (HPLC) method, as was described before [26]. The assays were
reproducible with low intra- and interday variation (coefficient of
variation<10%). The extraction efficiencies of the analyzed com-
pounds and the internal standard ranged from 66% to 95%. Con-
centrations of antidepressants were expressed for the wet brain tissue in
ng/g.
2.7. Statistical analysis
t-Test or two-way analysis of variance (ANOVA) followed by
Bonferroni’s post-hoc test were applied, depending on the experimental
design. The outcomes were given as the means ± standard error of the
mean (SEM). When p < 0.05, differences between the compared
groups were treated as significant.
3. Results
3.1. Effects of a concurrent administration of JWH133 and the tested
antidepressants in the FST
A single administration of JWH133 (0.25mg/kg) or a given anti-
depressant drug (i.e., imipramine – 15mg/kg, escitalopram – 2mg/kg,
or reboxetine – 2.5 mg/kg) did not significantly influence the im-
mobility time of animals in the FST. When the tested substances were
injected in respective combinations, the treated mice were swimming
for a longer time than their control counterparts (Fig. 1A). Two-way
ANOVA presented: (1) a significant JWH133-imipramine interaction [F
(1,28)= 8.57; p= 0.0067] with a significant effect of JWH133 [F
(1,28)= 10.24; p=0.0034] and a significant effect of imipramine [F
(1,28)= 23.14; p < 0.0001], (2) a significant JWH133-escitalopram
interaction [F(1,26)= 4.95; p=0.0351] with a significant effect of
JWH133 [F(1,26)= 8.85; p=0.0063] and a significant effect of esci-
talopram [F(1,26)= 22.22; p < 0.0001], and (3) a significant
JWH133-reboxetine interaction [F(1,28)= 10.87; p=0.0027] with a
significant effect of JWH133 [F(1,28)= 12.89; p= 0.0012] and a sig-
nificant effect of reboxetine [F(1,28)= 27.14; p < 0.0001].
3.2. Effects of a concurrent administration of AM630 and the tested
antidepressants in the FST
Concurrent administration of the sub-effective doses of AM630
(0.25 mg/kg) and the antidepressant drug (i.e., imipramine – 15mg/kg,
escitalopram – 2mg/kg, or reboxetine – 2.5mg/kg) increased activity
of the tested mice in the FST, which was presented in Fig. 2A. Two-way
ANOVA demonstrated: (1) a significant AM630-imipramine interaction
[F(1,26)= 4.34; p=0.0472] with a significant effect of AM630 [F
(1,26)= 11.98; p= 0.0019] and a significant effect of imipramine [F
(1,26)= 15.29; p=0.0006], (2) a significant AM630-escitalopram
interaction [F(1,24)= 6.63; p= 0.0166] with a significant effect of
AM630 [F(1,24)= 13.94; p=0.0010] and a significant effect of esci-
talopram [F(1,24)= 12.42; p=0.0017], and (3) a significant AM630-
reboxetine interaction [F(1,28)= 7.79; p=0.0094] with a significant
effect of AM630 [F(1,28)= 10.14; p=0.0035] and a significant effect
of reboxetine [F(1,28)= 14.32; p=0.0007].
3.3. Effects of a concurrent administration of JWH133 and the tested
antidepressants in the TST
Mice treated with a single injection of JWH133 (0.25mg/kg) or a
given antidepressant drug (i.e., imipramine – 15mg/kg, escitalopram –
2mg/kg, or reboxetine – 2.5 mg/kg) stayed immobile for the same
duration of time as the animals from the control group. However, when
the tested substances were injected in respective combinations, the
antidepressant-like effect was detected in the TST (Fig. 1B). The fol-
lowing significant drug-drug interactions were revealed by two-way
ANOVA analysis: (1) a significant JWH133-imipramine interaction [F
(1,26)= 4.73; p= 0.0389] with a significant effect of JWH133 [F
(1,26)= 8.17; p=0.0083] and a significant effect of imipramine [F
(1,26)= 16.48; p=0.0004], (2) a significant JWH133-escitalopram
interaction [F(1,28)= 8.73; p= 0.0063] with a significant effect of
JWH133 [F(1,28)= 12.82; p=0.0013] and a significant effect of es-
citalopram [F(1,26)= 12.42; p= 0.0015], and (3) a significant
JWH133-reboxetine interaction [F(1,28)= 5.56; p=0.0255] with a
significant effect of JWH133 [F(1,28)= 8.13; p= 0.0081] and a sig-
nificant effect of reboxetine [F(1,28)= 16.25; p=0.0004].
3.4. Effects of a concurrent administration of AM630 and the tested
antidepressants in the TST
After a single administration of AM630 (0.25mg/kg) or a given
antidepressant drug (i.e., imipramine – 15mg/kg, escitalopram – 2mg/
kg, or reboxetine – 2.5 mg/kg), behavior of the treated mice in the TST
was similar to the one observed for animals from the control group. By
contrast, co-administration of AM630 with a given antidepressant drug
significantly reduced the immobility time of animals (Fig. 2B). Two-
way ANOVA demonstrated: (1) a significant AM630-imipramine inter-
action [F(1,28)= 9.18; p=0.0052] with a significant effect of AM630
[F(1,28)= 10.38; p=0.0019] and a significant effect of imipramine [F
(1,28)= 10.65; p=0.0029], (2) a significant AM630-escitalopram
interaction [F(1,24)= 4.60; p= 0.0424] with a significant effect of
AM630 [F(1,24)= 6.28; p= 0.0194] and a significant effect of esci-
talopram [F(1,24)= 18.63; p=0.0002], and (3) a significant AM630-
reboxetine interaction [F(1,28)= 9.64; p=0.0043] with a significant
effect of AM630 [F(1,28)= 11.26; p=0.0023] and a significant effect
of reboxetine [F(1,28)= 25.20; p < 0.0001].
3.5. Effects of a concurrent administration of JWH133 or AM630 and the
tested antidepressants on the spontaneous locomotor activity of mice
As presented in Table 1, neither a single administration of the tested
CB2 receptor ligands or antidepressants nor their respective combina-
tions influenced the spontaneous locomotor activity of animals.
3.6. Pharmacokinetic studies
Outcomes of the pharmacokinetic studies demonstrated that none of
the tested CB2 receptor ligands (i.e., JWH133 – 0.25mg/kg or AM630 –
0.25mg/kg) elevated the brain levels of imipramine, desipramine, es-
citalopram, and reboxetine (Table 2). t-test revealed the following re-
sults: (1) t(14)= 1.276, p= 0.2226 for the JWH133-imipramine
(15mg/kg) combination, (2) t(14)= 0.6404, p= 0.5323 for the
JWH133-desipramine (an active metabolite of imipramine)
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combination, (3) t(18)= 0.7445, p= 0.4689 for the JWH133-escita-
lopram (2mg/kg) combination, (4) t(14)= 0.1032, p=0.9193 for the
JWH133-reboxetine (2.5 mg/kg) combination, (5) t(14)= 0.3359,
p=0.7419 for the AM630-imipramine (15mg/kg) combination, (6) t
(14)= 0.1095, p=0.9144 for the AM630-desipramine combination,
(7) t(14)= 0.8318, p=0.4195 for the AM630-escitalopram (2mg/kg)
combination, and (8) t(14)= 0.005376, p=0.9958 for the AM630-
reboxetine (2.5 mg/kg) combination.
4. Discussion
In the course of intensive studies over the pathomechanism of
depression, the endocannabinoid system has emerged as an important
item in the development and/or treatment of this disease. Medical and
scientific bases provide discrepant information on the cannabinoids
effects in mood disorders. Both the pro-depressive and antidepressant
activity have been recorded after cannabis consumption, and these ef-
fects use to be attributed exclusively to CB1 receptors. However, quite
recently it has been proved that CB2 receptors can also be found in
different brain areas, including those responsible for emotions, like the
prefrontal cortex, hippocampus, or amygdala [4,11,17,29]. Thus, CB2
receptors seem to be also involved in mood changes in humans, though
their impact is still relatively poorly documented. Several authors
suggest that CB2 receptors could be an interesting novel target for the
Fig. 1. Effect of a combined intraperitoneal administration of JWH133 and antidepressant drugs in (A) the FST and (B) the TST in mice.
Imipramine (15mg/kg), escitalopram (2mg/kg), and reboxetine (2.5mg/kg) were injected 60min before testing, whereas JWH133 (0.25mg/kg) was given 30min
before the experiment. The values represent mean+SEM (n=7–8 mice per group). ^^p< 0.01, ^^^p< 0.001 versus respective antidepressant drug; ***p < 0.001
versus JWH133 (two-way ANOVA followed by Bonferroni's post-hoc test).
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treatment of depressive disorders, including the post-stroke depression
[17,21].
The antidepressant potential of JWH133 (0.5–1mg/kg) – the CB2
receptor agonist applied in our study, was observed by Kruk-Słomka
et al. [20] in the FST in Swiss mice. The authors demonstrated that the
JWH133 treatment exerted the U-shaped anti-immobility pattern, with
ineffectiveness of the lowest (0.25mg/kg) and the highest (2 mg/kg)
tested doses. As for the AM630 – the CB2 receptor inverse agonist, re-
sults from the behavioural studies are controversial. In the above-
mentioned experiments carried out by the team of Kruk-Słomka [20],
only its lowest tested dose (i.e., 0.5 mg/kg) was effective in the FST,
whereas the concentrations of 1–3mg/kg did not increase the swim-
ming time of animals. Quite contrary were the outcomes reported by
García-Gutiérrez et al. [17] who demonstrated that an acute adminis-
tration of 1–3mg/kg of AM630 produced an antidepressant-like activity
in the FST, but only in the wild type of swiss ICR mice; these doses did
not change the behaviour of animals with experimentally-induced
overexpression of the CB2 receptors. In fact, the authors revealed that
after an acute and chronic administration of AM630 different effects in
the biochemical and behavioural tests measuring the depression level in
rodents may be recorded, depending on the applied experimental
conditions. A 4-week administration of this CB2 receptor ligand in the
Fig. 2. Effect of a combined intraperitoneal administration of AM630 and antidepressant drugs in (A) the FST and (B) the TST in mice.
Imipramine (15mg/kg), escitalopram (2mg/kg), and reboxetine (2.5 mg/kg) were injected 60min before testing, whereas AM630 (0.25mg/kg) was given 30min
before the experiment. The values represent mean+SEM (n=7–8 mice per group). ^^p< 0.01, ^^^p< 0.001 versus respective antidepressant drug; ***p < 0.001
versus AM630 (two-way ANOVA followed by Bonferroni's post-hoc test).
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stressed wild-type ICR Swiss mice prevented the development of de-
pression-like behaviour measured by the TST and by the sucrose intake
test, whereas such a treatment had no impact on the behaviour of the
non-stressed wild-type animals. Furthermore, the AM630 therapy per se
did not influence the expression of the CB2 receptor, BDNF gene, or the
BDNF protein level in the hippocampus, but this CB2 receptor ligand
significantly reduced the BDNF loss and reversed the reduction in CB2
receptor levels induced by the unpredictable chronic mild stress [17].
To our knowledge, the present study is the first one that assessed the
influence of CB2 receptor ligands on the activity of conventional anti-
depressant drugs that affect the monoaminergic system. We examined
the impact of co-administration of CB2 receptor agonist (JWH133) or
CB2 receptor antagonist (AM630) and imipramine (a tricyclic anti-
depressant), escitalopram (a selective serotonin reuptake inhibitor), or
reboxetine (a selective inhibitor of noradrenalin reuptake) on the de-
pression-related behaviour of mice in the FST and the TST, i.e. two most
widely used animal tests evaluating the antidepressant-like activity. We
demonstrated that JWH133 and AM630 when administered at per se
inactive dose of 0.25mg/kg significantly intensified the antidepressant
effects of the applied drugs (also given at the sub-effective doses:
15mg/kg of imipramine, 2mg/kg of escitalopram, and 2.5mg/kg of
reboxetine), suggesting an addition or synergism of action. Mice that
received single injections of respective combinations (imipramine-, es-
citalopram-, or reboxetine-CB2 receptor ligand) were more mobile in
the FST and the TST than animals from the control groups. According to
the literature data [30,31] this observation can be treated as an in-
dicator of the antidepressant behaviour. Similarly to our observations,
both JWH133 and AM630 when given at a non-effective dose of 2mg/
kg significantly potentiated the antidepressant activity of an antagonist
of the muscarinic acetylcholine receptors, i.e. scopolamine, in the FST
in Swiss mice [20]. Though there are reports that CB2 receptor agonists
and antagonists may alter spontaneous locomotor activity of animals in
a strain- and gender-dependent manner [4], we did not notice any
differences in locomotion of mice from the tested and control groups.
Similarly, in experiments by Kruk-Słomka et al. [20] no stimulant/in-
hibitory action of JWH133 (0.25–2mg/kg) or AM630 (0.5–3mg/kg)
was noticed. Consequently, it is improbable that the antidepressant-like
effects observed in the behavioural tests in the present study were false
positive.
Generally, the molecular mechanism of the antidepressant-like ac-
tivity of CB receptor ligands seems to be very complicated and complex.
It has not been fully understood yet. Strangely enough, both CB1 and
CB2 receptor agonists and antagonists may exert the antidepressant-like
activity in rodents as well as they can induce the pro-depressive be-
haviour in animals. Moreover, it was found out that administration of
the inactive dose of both CB2 receptor antagonist (AM630, 2mg/kg)
and CB1 antagonist (AM251, 0.25mg/kg) is able to abolish the anti-
depressant-like effects of the active doses of CB2 receptor agonist
(JWH133, 0.5 and 1mg/kg) in the FST in naïve Swiss mice. Similarly,
in the same strain of rodents, administration of the non-effective dose of
both CB2 receptor antagonist (AM630, 2mg/kg) and CB1 antagonist
(AM251, 0.25mg/kg) is able to reverse the antidepressant-like effects
of the active doses of CB1 receptor agonist (oleamide, 10 and 20mg/kg)
[20]. In fact, Onaivi et al. [4] noted that in different neuronal popu-
lations CB1 and CB2 receptors work to a certain point independently,
but to a certain point also cooperatively in regulation of diverse phy-
siological activities affected by cannabinoids. Viewing the above-men-
tioned, it should not be surprising that both JWH133 and AM630, i.e.,
the compounds that should act oppositely, potentiated the activity of
the tested antidepressants in our study. Most probably, elevation of the
serotonin and/or noradrenaline levels leading to potentiation of the
serotonergic and/or noradrenergic neurotransmissions was responsible
for the observed effects. Both the tested antidepressant drugs as well as
cannabinoids are believed to modulate the monoaminergic system [32].
Table 1
Effect of a combined intraperitoneal administration of (A, B) JWH133 or (C, D)
AM630 and antidepressant drugs on the spontaneous locomotor activity of
mice.
Treatment Travelled distance (cm)
(A) vehicle+ vehicle 474.4 ± 49.66
JWH133+vehicle 400.6 ± 51.81
imipramine+ vehicle 365.0 ± 46.23
imipramine+ JWH133 517.4 ± 87.69
reboxetine+ vehicle 310.0 ± 55.38
reboxetine+ JWH133 418.4 ± 55.94
(B) vehicle+ vehicle 613.0 ± 48.68
JWH133+vehicle 597.6 ± 50.41
escitalopram+vehicle 777.4 ± 78.87
escitalopram+ JWH133 784.87 ± 47.74
(C) vehicle+ vehicle 526.0 ± 41.97
AM630+ vehicle 572.5 ± 48.02
imipramine+ vehicle 559.6 ± 66.81
imipramine+AM630 562.7 ± 38.49
escitalopram+vehicle 667.9 ± 63.89
escitalopram+AM630 818.3 ± 41.97
(D) vehicle+ vehicle 518.5 ± 68.85
AM630+ vehicle 388.4 ± 53.41
reboxetine+ vehicle 366.4 ± 54.92
reboxetine+AM630 432.5 ± 17.95
Imipramine (15mg/kg), escitalopram (2mg/kg), and reboxetine (2.5mg/kg)
were injected 60min before testing, whereas JWH133 (0.25mg/kg) and
AM630 (0.25mg/kg) were given 30min before the experiment. The values
represent mean ± SEM (n=7–8 mice per group). Two-way ANOVA was used
for statistical analysis.
Table 2
Effect of JWH133 and AM630 on the brain levels of antidepressants in mice.
Treatment Drug/metabolite level in the brain (ng/g) Treatment Drug/metabolite level in the brain (ng/g)
imipramine level imipramine level
imipramine+vehicle 22407 ± 3021 imipramine+vehicle 5358 ± 1098
imipramine+ JWH133 18011 ± 1654 imipramine+AM630 5989 ± 1525
desipramine level desipramine level
imipramine+vehicle 2118 ± 484.4 imipramine+vehicle 441.3 ± 74.48
imipramine+ JWH133 1720 ± 386.9 imipramine+AM630 430.0 ± 70.79
escitalopram level escitalopram level
escitalopram+vehicle 507.1 ± 46.28 escitalopram+vehicle 88.89 ± 18.40
escitalopram+ JWH133 430.5 ± 91.96 escitalopram+AM630 70.84 ± 11.51
reboxetine level reboxetine level
reboxetine+ vehicle 51.49 ± 6.134 reboxetine+ vehicle 54.95 ± 6.298
reboxetine+ JWH133 52.48 ± 7.348 reboxetine+AM630 54.90 ± 7.158
Imipramine (15mg/kg), escitalopram (2mg/kg), and reboxetine (2.5 mg/kg) were injected 60min before testing, whereas JWH133 (5mg/kg) and AM630 (0.25mg/
kg) were given 30min before decapitation. The values represent mean ± SEM (n=6–8 mice per group). t-test was used for statistical analysis.
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Franklin et al. [33] demonstrated that CB2 receptors are implicated in
the cannabinoid-induced upregulation of the serotonergic 5-HT2A re-
ceptors in the brain. This effect is most probably mediated by inter-
nalization of CB2 receptors and stimulation of the ERK1/2 signalling
pathway. Disturbances in the 5-HT2A receptor-dependent signalling are
involved in the pathomechanism of different neuropsychiatric dis-
orders, like schizophrenia, anxiety, or depression [34,35]. It is also
possible that CB2 receptors modulate the depression-related responses
via alteration in immune system. Their increased expression in the brain
was observed after an intra-striatal administration of lipopoly-
saccharide in a rat model of Parkinson’s disease and it corresponded
with an activation of the microglia [36]. In experiments by Zoppi et al.
[13], activation of CB2 receptors by experimentally-induced over-
expression or administration of an CB2 receptor agonist in ICR Swiss
mice exerted the anti-inflammatory or neuroprotective effects via con-
trol of glutamate uptake, whereas CB2 receptors knock-out potentiated
stress-induced neuroinflammatory responses. A specific role of neuro-
immune interactions in the development of psychiatric disorders has
been examined for decades and a range of diverse studies have de-
monstrated a clear link between chronic immune responses and oc-
currence of depression [37]. Stimulation of CB2 receptors in the brain is
also known to reduce expression of inducible nitric oxide synthase,
production of nitric oxide, generation of reactive oxygen/nitrogen
species, and thus, to attenuate the oxidative stress [38]. Additionally,
neither JWH133 nor AM630 are exclusively specific for CB2 receptors,
but they are only CB2 receptor-selective. They also exhibit partial affi-
nity for CB1 receptors [39,40]. Therefore, pathways connected with CB1
receptors may also contribute to the effects detected in our experi-
ments.
Since the pharmacokinetic assays showed that neither JWH133 nor
AM630 enhanced the brain levels of the tested antidepressant drugs
(i.e., imipramine with its active metabolite – desipramine, escitalo-
pram, or reboxetine), it should be assumed that the potentiation of the
antidepressant effect observed in our study took place in the pharma-
codynamic phase instead of in the pharmacokinetic one. However,
based on the experiments of Smaga et al. [41], it is highly unlikely that
an acute administration of the antidepressant drugs applied in our study
might have changed the expression of cannabinoid receptors (either
CB1 or CB2) in the mouse brain. Such effects couldn’t be ruled out after
prolonged (14-day) treatment. Reduced levels of CB1 and/or CB2 re-
ceptors were detected in the dorsal striatum, nucleus accumbens, and/
or cerebellum of male Wistar rats exposed to imipramine (15mg/kg),
whereas increased levels of CB1 and/or CB2 receptors in the hippo-
campus and/or prefrontal cortex with decreased levels of CB1 receptors
in dorsal striatum were recorded after escitalopram treatment (10mg/
kg) [41]. In the view of the above, further studies over the molecular
mechanism of the interactions demonstrated in our experiments are
needed.
5. Conclusions
The results of the present study revealed that both activation and
inhibition of the CB2 receptor function have a potential to strengthen
the antidepressant activity of drugs targeting the monoaminergic
system. Most probably, the described interaction has a pharmacody-
namic background. Though our findings should be treated as the pre-
liminary ones, we assume that the modulation of the endocannabinoid
neurotransmission via CB2 ligands could be a promising strategy as an
adjuvant treatment in patients with depression. Such an approach could
have additional benefits, since the CB2 selective ligands are thought to
be devoid of central nervous system side effects that may limit the
clinical use of other substances with antidepressant potential [19].
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